Loading clinical trials...
Loading clinical trials...
This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Five Prime Therapeutics, Inc.
NCT01846520 · Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, and more
NCT01108003 · Recurrent Bladder Cancer, Stage 0 Bladder Cancer, and more
NCT02252393 · Recurrent Bladder Cancer, Stage 0 Bladder Cancer, and more
NCT00471536 · Distal Urethral Cancer, Proximal Urethral Cancer, and more
NCT01639521 · Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions